Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved

Arne MørkJ Arnt


Second-generation antipsychotics have some beneficial effect on cognition. Recent studies, furthermore, indicate differential effects of second-generation antipsychotics on impairment in executive cognitive function. We evaluated the effect of the second-generation antipsychotic drug, sertindole, on extracellular levels of dopamine (DA), acetylcholine (ACh), and glutamate (Glu) in the rat medial prefrontal cortex (mPFC). Risperidone was studied for comparison. Moreover, selective serotonin 5-HT(2A), 5-HT(2C), and 5-HT(6) receptor antagonists were used, given alone and in combination with the preferential DA D(2) receptor antagonist, haloperidol, to further clarify the action of the two drugs. Rats were treated acutely with vehicle or drugs, and extracellular levels of neurotransmitters were assessed by microdialysis in freely moving animals. Sertindole and risperidone significantly increased extracellular levels of DA. Haloperidol; the 5-HT(2A) receptor antagonist, M100907; the 5-HT(2C) receptor antagonist, SB242084; and the 5-HT(6) receptor antagonist, GSK-742457, induced minor increases in levels of DA, but the three latter compounds raised the DA levels notably in combination with haloperidol. Sertindole and risperidone sign...Continue Reading


Oct 31, 2012·Current Opinion in Psychiatry·Bronwyn Hegarty, Gordon Parker
Sep 22, 2010·Drug Design, Development and Therapy·Maria Rosaria Anna MuscatelloRocco A Zoccali
Aug 2, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria Anna MuscatelloRocco A Zoccali
Sep 21, 2012·Expert Opinion on Drug Safety·Evangelos KaramatskosDieter Naber
Nov 19, 2011·The International Journal of Neuropsychopharmacology·Neil E PatersonTaleen Hanania
Mar 27, 2012·Journal of Pharmacological Sciences·Yu OhmuraMitsuhiro Yoshioka
Jul 31, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Monica M MarcusTorgny H Svensson
Feb 17, 2018·Pharmaceutical Research·Willem Johan van den BrinkElizabeth Cunera Maria de Lange
Jun 21, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kenji MaedaTetsuro Kikuchi
Feb 26, 2016·Therapeutic Advances in Psychopharmacology·Saibal DasIndranil Saha
Feb 7, 2014·Reviews in the Neurosciences·Agnieszka Nikiforuk
Nov 18, 2010·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinMarc Adida
Apr 2, 2015·Journal of Clinical Psychopharmacology·Rocco A ZoccaliMaria Rosaria Anna Muscatello


Jan 1, 1984·Journal of Neurochemistry·F Fonnum
Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, Robert H Roth
May 27, 1999·Molecular and Chemical Neuropathology·K A Skau, C G Triplett
Jun 24, 1999·The Journal of Comparative Neurology·V Cornea-HébertL Descarries
Feb 9, 2000·Psychopharmacology·G Remington, S Kapur
Feb 23, 2000·The Journal of Comparative Neurology·R L Jakab, P S Goldman-Rakic
Aug 6, 2000·British Journal of Pharmacology·C RoutledgeD N Middlemiss
Sep 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Y NodaT Nabeshima
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee A DawsonP Li
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Junji IchikawaHerbert Y Meltzer
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sudabeh Shirazi-SouthallGeorge G Nomikos
Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Susan M CochranBrian J Morris
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Sep 24, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yukio AgoToshio Matsuda
Jul 7, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elizabeth A PehekOmar S Mabrouk
Nov 10, 2005·Journal of Neurochemistry·A BortolozziF Artigas
Dec 1, 2005·International Clinical Psychopharmacology·Jean-Michel AzorinHenrik Loft
Jun 22, 2006·Current Topics in Medicinal Chemistry·Arne Schousboe, Helle S Waagepetersen
Aug 22, 2006·CNS & Neurological Disorders Drug Targets·Martyn D WoodDeclan N C Jones
Jan 30, 2007·Journal of Psychopharmacology·James M StoneLyn S Pilowsky

Related Concepts

Hepatitis D Infection
Serotonin 6 receptor
Antipsychotic Effect
Receptor, Serotonin,5-HT2A
Assay OF Haloperidol
Prefrontal Cortex
Serotonin Measurement
Antagonist Muscle Action

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here